硅胶乳房植入物在初次隆乳患者中的安全性与有效性:真实世界研究
结果显示50/777例(6.4%)患者报告并发症,平均发生时间为术后3.9年(范围19天至11.8年),10年累积包膜挛缩(Baker III/IV级)、感染和破裂发生率分别为4.7%、0.1%和1.6%。
要点
- 10年累积包膜挛缩(Baker III/IV级)发生率为4.7%,感染为0.1%,破裂为1.6%。
- 6.4%患者报告并发症,平均发生时间为术后3.9年,范围19天至11.8年。
- 真实世界数据支持MemoryGel假体在初次隆乳中的长期安全性和有效性。
核心结论
- 单中心大样本分析进一步支持MemoryGel乳房假体在初次隆乳队列中的长期安全性和有效性。
研究设计与样本
- 采用描述性统计总结基线特征和结局,Kaplan-Meier模型估计包膜挛缩(Baker III/IV级)、感染和破裂的安全性结局。
主要发现
- 共50/777例(6.4%)患者报告并发症,平均并发症发生时间为术后3.9年(范围19天至11.8年)。
- 10年累积包膜挛缩(Baker III/IV级)发生率为4.7%。
- 10年累积感染发生率为0.1%。
- 10年累积破裂发生率为1.6%。
临床怎么用
- 可为初次隆乳患者提供MemoryGel假体长期安全性数据,辅助术前咨询和术后随访规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results from the MemoryGel Breast Implants Core Clinical Study suggest these devices are safe and effective at 10 years after implantation. Although clinical trials are essential for measuring the safety and effectiveness of a device, real-world evidence can supplement clinical trials by providing information on outcomes observed in diverse clinical settings for a more heterogeneous population, without fixed treatment patterns, and without continuous patient monitoring, such that follow-up is more representative of normal clinical practice. OBJECTIVES: The aim of this study was to measure real-world outcomes, including safety and effectiveness, in patients who underwent primary breast augmentation with smooth MemoryGel implants. METHODS: This was a case series looking at patients, age 22 years and older, who underwent primary breast augmentation at a single site between December 2006 and December 2016 and who had a minimum of 2 years of follow-up. Descriptive statistics were used to summarize baseline characteristics and outcomes. Kaplan-Meier models were used to estimate safety outcomes for capsular contracture (Baker grade III/IV), infection, and rupture. RESULTS: A total of 50/777 (6.4%) patients reported a complication, with an average time to complication of 3.9 years (range, 19 days-11.8 years) postprocedure. Kaplan-Meier estimates of the 10-year cumulative incidence of capsular contracture (Baker grade III/IV), infection, and rupture were 4.7%, 0.1%, and 1.6%, respectively. CONCLUSIONS: Analyses of a large population from a single site provide further support for the long-term safety and effectiveness of MemoryGel breast implants in a primary augmentation cohort.
引用
- Maxwell D, Estes M, Walcott JM, et al. Safety and Effectiveness of Silicone Gel-Filled Breast Implants in Primary Augmentation Patients. Aesthet Surg J. 2021. PMID: 33647937. doi:10.1093/asj/sjaa388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。